静脉注射甲基普雷迪尼索隆作为慢性炎症性脱髓化多基基隆神经病的附加诱导疗法:一项随机对照试验
Sander R M Bus1, Iris N van Doorn1, Laura Zambreanu2
1Department of Neurology, Amsterdam UMC Location AMC, Amsterdam, The Netherlands.
Journal of neurology, neurosurgery, and psychiatry
|February 27, 2026
概括
将静脉注射的甲基普雷迪尼索隆添加到静脉注射的免疫球蛋白中,用于慢性炎症性脱髓化多基原蛋白神经病症 (CIDP),并没有改善缓解率. 由于安全问题,特别是血栓塞栓事件,联合治疗被提前停止.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 临床试验 临床试验
背景情况:
- 慢性炎症性脱髓化多基原蛋白神经病变 (CIDP) 通常需要长期治疗.
- 维持治疗对于管理CIDP患者至关重要.
研究的目的:
- 评估是否将静脉注射免疫球蛋白 (IVIg) 与静脉注射甲基前素 (IVMP) 结合起来,与单独IVIg相比,可以提高CIDP患者的缓解率.
- 评估IVIg和IVMP联合治疗的安全性和有效性.
主要方法:
- 进行了一项随机,双盲,安慰剂控制的试验.
- 成年CIDP患者每3周接受IVMP (1000毫克) 或安慰剂,持续18周,同时接受标准IVIg治疗.
- 缓解被定义为在52周没有进一步治疗的情况下,残疾等级持续改善.
主要成果:
- 由于安全问题,该研究被提前终止,IVIg/IVMP组有4次血栓栓塞发事件,IVIg/安慰剂组没有.
- 在52周内,IVIg/IVMP的缓解率为38%,IVIg/安慰剂为28% (p=0.47).
- 二次结果表明,IVIg/IVMP组在18周和52周的残疾和损伤有更大的改善.
结论:
- 在本研究中,联合IVIg和IVMP治疗并没有显著增加CIDP的缓解率.
- 由于安全问题,特别是与联合治疗相关的血栓栓塞事件,研究过早停止.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
608
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
608
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
577
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
577
01:29Inflammatory Bowel Disease IV: Pharmacological Management
862
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
862